| Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing P Galanos, K Vougas, D Walter, A Polyzos, A Maya-Mendoza, ... Nature cell biology 18 (7), 777-789, 2016 | 278 | 2016 |
| Unreplicated DNA remaining from unperturbed S phases passes through mitosis for resolution in daughter cells A Moreno, JT Carrington, L Albergante, M Al Mamun, EJ Haagensen, ... Proceedings of the National Academy of Sciences 113 (39), E5757-E5764, 2016 | 129 | 2016 |
| The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition EJ Haagensen, S Kyle, GS Beale, RJ Maxwell, DR Newell British journal of cancer 106 (8), 1386-1394, 2012 | 90 | 2012 |
| Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer G Beale, EJ Haagensen, HD Thomas, LZ Wang, CH Revill, SL Payne, ... British journal of cancer 115 (6), 682-690, 2016 | 53 | 2016 |
| TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: pre-clinical and clinical data Z Gamie, K Kapriniotis, D Papanikolaou, E Haagensen, RDC Ribeiro, ... Cancer letters 409, 66-80, 2017 | 43 | 2017 |
| The high-affinity interaction between ORC and DNA that is required for replication licensing is inhibited by 2-arylquinolin-4-amines NJ Gardner, PJ Gillespie, JT Carrington, EJ Shanks, SP McElroy, ... Cell chemical biology 24 (8), 981-992. e4, 2017 | 20 | 2017 |
| Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity … EJ Haagensen, HD Thomas, C Mudd, E Tsonou, CM Wiggins, RJ Maxwell, ... European Journal of Cancer 56, 69-76, 2016 | 19 | 2016 |
| The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour … EJ Haagensen, HD Thomas, I Wilson, SJ Harnor, SL Payne, T Rennison, ... PLoS One 8 (12), e81763, 2013 | 16 | 2013 |
| Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037 EJ Haagensen, HD Thomas, WA Schmalix, AC Payne, L Kevorkian, ... Cancer Chemotherapy and Pharmacology 78, 1269-1281, 2016 | 9 | 2016 |
| Pandemic-era digital education: insights from an undergraduate medical Programme ID Keenan, E Green, E Haagensen, R Hancock, KS Scotcher, ... Biomedical Visualisation: Volume 14‒COVID-19 Technology and Visualisation …, 2022 | 3 | 2022 |
| Co‑localisation of intra‑nuclear membrane type‑1 matrix metalloproteinase and hypoxia inducible factor‑2α in osteosarcoma and prostate carcinoma cells CD Chan, EJ Haagensen, HA Tensaout, KJ Rennie, Z Gamie, J Barry, ... Oncology Letters 21 (2), 1-1, 2021 | 2 | 2021 |
| The location and development of Replicon Cluster Domains i n early replicating DNA [version 1; peer review: 2 approved with JA da Costa-Nunes, M Gierlinski, T Sasaki, EJ Haagensen, DM Gilbert, ... | | 2023 |
| The location and development of Replicon Cluster Domains in early replicating DNA JA da Costa-Nunes, M Gierlinski, T Sasaki, EJ Haagensen, DM Gilbert, ... Wellcome Open Research 8, 2023 | | 2023 |
| The Effects of Integrative Study Support on the Type and Complexity of Student Study Skills Techniques EJ Haagensen, MBC Pancho, S Walker, B Veasuvalingam, B Madelar, ... 4th Developing Excellence in Medical Education Conference (DEMEC), 2021 | | 2021 |
| Komselic ES, Gourgolis VG, Newman TJ, Blow JJ. A Moreno, JT Carrington, L Albergante, M AlMamuna, EJ Haagensen | | 2017 |
| Pre-clinical evaluation of P13K and MEK inhibitor combinations in colorectal cancer tumour models EJ Haagensen University of Newcastle Upon Tyne, 2012 | | 2012 |
